Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$8.48 - $14.97 $1.54 Million - $2.72 Million
182,024 Added 35.23%
698,770 $10.4 Million
Q3 2022

Nov 14, 2022

SELL
$6.61 - $8.72 $49,330 - $65,077
-7,463 Reduced 1.42%
516,746 $4.25 Million
Q2 2022

Aug 12, 2022

SELL
$3.51 - $6.67 $449 - $853
-128 Reduced 0.02%
524,209 $3.44 Million
Q1 2022

May 12, 2022

SELL
$3.15 - $6.01 $10,990 - $20,968
-3,489 Reduced 0.66%
524,337 $2.93 Million
Q4 2021

Feb 10, 2022

SELL
$4.69 - $7.4 $22,413 - $35,364
-4,779 Reduced 0.9%
527,826 $2.48 Million
Q3 2021

Nov 09, 2021

BUY
$5.12 - $6.89 $275,522 - $370,771
53,813 Added 11.24%
532,605 $3.29 Million
Q2 2021

Aug 11, 2021

BUY
$6.21 - $7.45 $2.97 Million - $3.57 Million
478,792 New
478,792 $3.15 Million

Others Institutions Holding AVEO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About AVEO PHARMACEUTICALS, INC.


  • Ticker AVEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,676,000
  • Description
  • AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...
More about AVEO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.